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Andrew S. MacDonald, PhD,b Steven C. Ley, PhD,a and Mark S. Wilson, PhDa London and Manchester, United KingdomBackground: The molecular and cellular pathways driving the
pathogenesis of severe asthma are poorly defined. Tumor
progression locus 2 (TPL-2) (COT, MAP3K8) kinase activates
the MEK1/2-extracellular-signal regulated kinase 1/2 MAP
kinase signaling pathway following Toll-like receptor, TNFR1,
and IL-1R stimulation.
Objective: TPL-2 has been widely described as a critical
regulator of inflammation, and we sought to investigate the role
of TPL-2 in house dust mite (HDM)-mediated allergic airway
inflammation.
Methods: A comparative analysis of wild-type and Map3k82/2
mice was conducted. Mixed bone marrow chimeras, conditional
knockout mice, and adoptive transfer models were also used.
Differential cell counts were performed on the bronchoalveolar
lavage fluid, followed by histological analysis of lung sections.
Flow cytometry and quantitative PCR was used to measure type
2 cytokines. ELISA was used to assess the production of IgE,
type 2 cytokines, and Ccl24. RNA sequencing was used to
characterize dendritic cell (DC) transcripts.
Results: TPL-2 deficiency led to exacerbated HDM-induced
airway allergy, with increased airway and tissue eosinophilia,
lung inflammation, and IL-4, IL-5, IL-13, and IgE production.
Increased airway allergic responses in Map3k82/2 mice were
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TPL-2 inhibited Ccl24 expression in lung DCs, and blockade of
Ccl24 prevented the exaggerated airway eosinophilia and lung
inflammation in mice given HDM-pulsed Map3k82/2 DCs.
Conclusions: TPL-2 regulates DC-derived Ccl24 production to
prevent severe type 2 airway allergy in mice. (J Allergy Clin
Immunol 2016;nnn:nnn-nnn.)
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Allergic asthma is a hyperinflammatory disease of the airways,
initiated in atopic individuals by allergen-presenting dendritic
cells (DCs) leading to the recruitment of cytokine-secreting T cells
and eosinophils to the lungs.1-3 Repeated allergen exposure results
in local tissue inflammation and remodeling with systemic
elevated levels of circulating IgE.4 Despite a good understanding
of the pathogenesis of allergic asthma, the mainstay for treatment
continues to be inhaled broad-scale corticosteroids, which have a
number of significant side effects. Furthermore, an increasing
number of patients are resistant to corticosteroid treatment5 and
there are an increasing number of patients who develop severe
asthma. Consequently, there is an urgent medical need to under-
stand in more detail the molecular mechanisms of severe allergic
asthma to identify new therapeutic targets.6,7
The mitogen activated protein-3 kinase tumor progression
locus 2 (TPL-2; also known as mitogen-activated protein kinase
kinase kinase 8 [MAP3K8] and cancer Osaka thyroid oncogene
[COT]) phosphorylates and activatesMEK1/2 after stimulation of
Toll-like receptors (TLRs) and the receptors for TNF and IL-1b,
leading to the activation of extracellular-signal regulated kinase
(ERK) 1/2 MAP kinases.8 The TPL-2/ERK1/2 signaling pathway
regulates cytokine and chemokine production in inflammatory re-
sponses.9-11 Studies with TPL-2–deficientMap3k82/2mice have
indicated that TPL-2 promotes inflammation in models of endo-
toxin shock, pancreatitis, liver fibrosis, and thrombocyto-
penia.9,12-14 TPL-2 is also required for proficient immunity to
intracellular bacterial and protozoan infection.15,16
We, and others, demonstrated that TPL-2 signaling in
radiation-resistant stromal cells, but not T cells or any other
hematopoietic cell, promotes the onset and severity of experi-
mental autoimmune encephalomyelitis, a model of multiple
sclerosis.17,18 Although these studies highlight the importance
of the TPL-2/MEK/ERK signaling axis in type 1 and TH17 im-
mune responses, the role of TPL-2 in mediating type 2 responses
has not been clearly established. A previous study suggested that
T-cell–intrinsic TPL-2 regulated CD41 TH2 cell differentiation
in vitro via ERK1/2 activation.19 The authors subsequently hy-
pothesized that increased type 2–associated ovalbumin-induced1
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cell–intrinsic deficiency of TPL-2; however, this was not tested.
In our studies, we found that T-cell receptor (TCR) activation of
ERK1/2 in purified CD41 T cells was completely independent of
TPL-2.17 These results prompted us to formally test whether T-
cell–intrinsic TPL-2 was required for type 2 immunity in vivo us-
ing a clinically relevant allergen, house dust mite (HDM),20 in
various models of allergic airway inflammation.
In the present study, we show that TPL-2 deficiency led to
severe HDM-induced airway allergy, when compared with wild-
type (WT) HDM-treated mice. Using adoptive transfer experi-
ments and cell lineage–specific conditional knockout mice, we
show that TPL-2 in T cells and B cells was not required for control
of severe airway allergy after HDM challenge. Rather, we found
an essential role for TPL-2 in DCs, restraining their promotion of
excessive airway inflammation. Using several in vivomodels with
genomewide RNA sequencing, we identified that TPL-2 regu-
lated the expression and production of Ccl24 (eotaxin-2) by
DCs. Furthermore, blocking Ccl24 in vivo abrogated the exacer-
bated airway inflammation induced by TPL-2–deficient DCs,
demonstrating a previously unappreciated role for DC-intrinsic
TPL-2 in regulating Ccl24 to limit severe airway allergy.METHODS
For detailed Methods, see this article’s Online Repository at www.
jacionline.org.RESULTS
TPL-2 inhibits HDM-induced airway allergy
Intraperitoneal allergen sensitization followed by localized
airway challenge is a well-established CD41 T-cell–dependent
model of airway allergy.21 To investigate the role of TPL-2 in
airway allergy, we sensitized and challenged WTandMap3k82/2
mice with HDM, one of the most common aeroallergens affecting
humans20 (Fig 1, A). One day after the final intratracheal
airway challenge, we observed significantly increased total
cellular infiltration in the bronchoalveolar lavage (BAL) fluid of
Map3k82/2mice comparedwithWTmice (Fig 1,B).We observed
no baseline differences between the 2 groups of mice after
PBS injection (Fig 1). Differential cell counts revealed that
Map3k82/2 mice had significantly increased numbers of
eosinophils, macrophages, neutrophils, and lymphocytes in
the BAL fluid (Fig 1, B). In addition, Map3k82/2 mice hadsignificantly increased numbers of eosinophils in the lung
compared with WT mice (see Fig E1, A, in this article’s Online
Repository at www.jacionline.org). Accompanying the increased
airway inflammation, we also observed augmented perivascular
and peribronchial tissue inflammation and a loss of lung
architecture in TPL-2–deficient mice (Fig 1, C). Consistent with
the increased pulmonary inflammation, we also observed a
significant increase in airway resistance in HDM-challenged
Map3k82/2mice upon administration of increasing doses ofmeth-
acholine compared with HDM-challenged WT mice (Fig 1, D).
In line with elevated airway and tissue inflammation in
Map3k82/2 mice, we observed an increased frequency and total
number of IL-4–, IL-5–, and IL-13–secreting TH2 cells, with
decreased IFN-g–secreting T cells in the lungs of Map3k82/2
mice compared with WT controls (Fig 1, E). The frequency of
IL-5– and IL-13–secreting group 2 innate lymphoid cells was un-
changed (Fig E1, B). Consistent with elevated lung TH2 cells,
Map3k82/2 mice had significantly increased mRNA expression
for type 2 cytokines Il5 and Il13 in the lung (Fig 1, F). Although
the expression of Ifngwas significantly reduced, that of Il4 remained
unchanged inMap3k82/2mice compared withWT controls (Fig 1,
F). In accordance with this, HDM-specific recall responses in the
local draining lymph node (LN) cultures revealed increased IL-5
and IL-13 production by Map3k82/2 mediastinal lymph node
(medLN) cells (Fig 1, G). Serum levels of IgE were also elevated
inMap3k82/2 mice compared with WT mice (Fig 1, H).
Activation of the TLR4 signaling pathway contributes signif-
icantly to airway allergy after HDM challenge.22,23 Given that
TPL-2 signals downstream of TLR4, we tested whether the
observed increased airway allergy in Map3k82/2 mice was
restricted toHDM-induced allergy. Sensitization and airway chal-
lenge with Der p1, the cysteine protease component of HDM or
chicken egg ovalbumin, also invoked significantly increased
allergic airway inflammation in Map3k82/2 mice, compared
with WTmice (Fig E1, C-F). Together, these data extend the pre-
vious report19 and clearly demonstrate an important regulatory
role for TPL-2 in modulating allergic airway responses in several
model systems.Neither T-cell–intrinsic nor B-cell–intrinsic TPL-2
regulates HDM-induced airway allergy
Although it was previously suggested that T-cell–intrinsic
TPL-2 was responsible for elevated airway inflammation in TPL-
2–deficient mice, this was not directly tested in vivo.19 We there-
fore assessed whether TPL-2 function specifically in T cells was
responsible for the increased allergic airway responses in com-
pleteMap3k82/2 mice, using 2 independent and complementary
approaches.
First, we established mixed bone marrow (BM) chimeric mice
with 80% Tcra2/2 BM cells mixed with 20% WT or 20%
Map3k82/2 BM cells transferred to Rag22/2 hosts. In the result-
ing chimeras, all the T cells developed from either WTor TPL-2–
deficient donor BM, whereas the majority (80%) of other hemato-
poietic cells were derived from TPL-2–sufficient Tcra2/2 BM.
Reconstitution of CD41 T cells between the 2 chimeric groups
was identical (Fig 2, A). Following HDM sensitization and airway
challenge, we observed no differences in the total cellular infiltra-
tion or the number of eosinophils in the BAL fluid of chimeric
mice withWT T cells or TPL-2–deficient T cells (Fig 2, B). Simi-
larly, pulmonary inflammation was comparable between the 2
FIG 1. Map3k82/2micemount enhancedairwayallergic responses comparedwithWTmice.A,Schematic rep-
resentation of the i.p. alum-basedHDMsensitization and i.t. HDMchallenge inWTandMap3k82/2mice.B,Dif-
ferential counts in the BAL fluid of PBS- and HDM-challenged WT andMap3k82/2 mice. C, Hematoxylin and
eosin (H&E)-stained histology sections and inflammation scores from PBS- and HDM-challenged lungs of
WT andMap3k82/2mice depicting cellular infiltration. D, Airway resistance (sRAW) measurement in allergic
WTandMap3k82/2mice in response to increasingdosesofmethacholine (3-50mg/mL).E,Frequencyand total
number of cytokine1/CD41/CD44hi cells in the lungs of PBS- and HDM-challengedWT andMap3k82/2mice as
assessed by intracellular cytokine staining. F, Lung expression of Ifng, Il4, Il5, and Il13 in PBS- and HDM-
challengedWT andMap3k82/2mice.G, HDM-specific IL-5 and IL-13 protein production as assessed by ELISA
in themedLN cell culture supernatants fromPBS- andHDM-challengedWT andMap3k82/2mice for 4 days.H,
Total IgE in the serum as assessed by ELISA from PBS- and HDM-challengedWT andMap3k82/2mice. All ex-
periments are representative of 2 to 3 independent experiments with 4 to 5 mice/genotype. The airway resis-
tance response is data combined from 2 independent experiments with n 5 4 mice/group. *P < .05 as
assessed by the 2-tailed Mann-Whitney test. i.p., Intraperitoneal; i.t., intratracheal.
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FIG 2. Increased airway allergic responses in Map3k82/2 mice is not a result of T-cell–intrinsic TPL-2 func-
tion.A, CD4 T-cell reconstitution in the lung andmedLNs of PBS- and HDM-challenged chimericmice.White
bars represent PBS-challenged chimeric mice with WT T cells, black bars represent HDM-challenged
chimeric mice with WT T cells, light gray bars represent PBS-challenged chimeric mice with Map3k82/2
T cells, and dark gray bars represent HDM-challenged chimeric mice withMap3k82/2 T cells. B, Differential
counts in the BAL fluid of PBS- and HDM-challenged chimeric mice. C, Hematoxylin and eosin–stained lung
histology sections and inflammation scores from PBS-challenged and allergic chimeric mice. D, Frequency
and total number of IL-4GFP1/CD41/CD44hi cells in the lungs of PBS- and HDM-challenged chimeric mice. E,
Lung expression of Il4, Il5, and Il13mRNA in PBS- and HDM-challenged chimeric mice. F, HDM-specific IL-5
and IL-13 protein production as assessed by ELISA in the medLN cell culture supernatants from PBS- and
HDM-challenged chimericmice for 4 days. All experiments are representative of 3 independent experiments
with 4 to 5 mice/genotype.
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Map3k82/2 Il4GFP1 mice was used to reconstitute the chimeric
mice, allowing us to track TH2 cells in the chimeric mice by flow
cytometry. We performed fluorescence-activated cell sorting anal-
ysis on the lungandLNcell populations and observedno significant
differences in the frequency and number of CD41CD44hiIl4GFP1
cells (Fig 2, D). Furthermore, no differences were detected in the
expression of Il4, Il5, and Il13 in the lungs of allergen-challenged
chimeric mice (Fig 2, E). Finally, HDM restimulation of medLN
cells from each group of chimeric mice resulted in similar levels
of IL-5 and IL-13 secretion (Fig 2, F).
Second, we used a Cre expression system under the Cd4 pro-
moter to delete TPL-2 in T cells using mice with a LoxP-flanked
Map3k8 allele. Concurrent deletion of a LoxP-flanked stop codon
ahead of the eYFP reporter under the Rosa26 promoter facilitated
evaluation of deletion efficiency. We sensitized and challenged
mice with TPL-2–sufficient (Cd4CreMap3k8fl/wt) or TPL-2–defi-
cient (Cd4CreMap3k8fl/ko) CD41 cells (see Fig E2, A and B, in
this article’s Online Repository at www.jacionline.org). In accor-
dance with the results obtained with chimeric mice, we found no
differences in the total cellular infiltration in the BAL fluid or the
number of eosinophils between Cd4CreMap3k8fl/ko mice and con-
trol Cd4CreMap3k8fl/wtmice (Fig E2, C). Pulmonary inflammation
was also comparable between the genotypes (Fig E2, D), with no
difference in mRNA expression for type 2 cytokines in the lung
(Fig E2, E) or the secretion of IL-5 and IL-13 by HDM-
restimulatedmedLN cells (Fig E2,F). Together, these complemen-
tary experiments clearly demonstrated that the enhanced allergic
responses to HDM in Map3k82/2 mice did not result from the
absence of TPL-2 expression in T cells alone. Consistent with
this conclusion, TPL-2–deficient T cells were comparable to WT
Tcells in their ability todifferentiate to theTH2 lineage andproduce
IL-4 in vitro (Fig E2, G).
Because various B-cell populations can regulate airway
allergy,24 we next tested the role of B-cell–intrinsic TPL-2, using
a similar mixed BM chimeric system with 80%muMTBMmixed
with 20%WTor20%Map3k82/2BMcells transferred toRag12/2
hosts. The resulting chimeric mice had similar reconstitution (see
Fig E3, A, in this article’s Online Repository at www.jacionline.
org) and upon HDM sensitization and airway challenge mounted
a comparable airway inflammatory response, with similar airway
infiltrates (Fig E3, B), comparable pulmonary inflammation
(Fig E3, C), similar expression of ll4GFP in CD41 cells in lung
and LN (Fig E3, D), lung mRNA expression for type 2 cytokines
(Fig E3, E), and HDM-specific cytokine secretion by restimulated
medLN cells (Fig E3, F). Together, these observations indicated
that the exacerbated allergic airway inflammation observed in
TPL-2–deficient mice was not due to the absence of TPL-2 in
the T-cell or B-cell compartments.TPL-2 function in CD11c1 DCs regulates HDM-
induced airway allergy
TPL-2 haswell-established signaling functions in innate immune
cells,8,10 including DCs, which are required for allergen-induced
airway inflammation.25 To test whether TPL-2 in CD11c1 DCs
regulated allergic airway responses, we restricted the deletion of
TPL-2 to CD11c1 cells using Cd11cCreMap3k8fl/ko mice and used
the expression of the eYFP reporter to evaluate the efficiency of
deletion (Fig 3, A). Following HDM sensitization and challenge
of Cd11cCreMap3k8fl/komice, we observed an increase in the influxof total cells and eosinophils in the BAL fluid, compared with
control Cd11cCreMap3k8wt/wt mice; however, this change was not
statistically significant (Fig 3, B). This trend was accompanied by
significantly increased inflammation in the lungs, with perivascular
and peribronchial cellular infiltration as well as loss of lung
architecture (Fig 3, C). We also detected a significant increase in
the frequency and total number of IL-5– and IL-13–secreting TH2
cells and a trend toward an increase in IL-4–secreting TH2 cells in
the lungs of Cd11cCreMap3k8fl/ko mice (Fig 3, D), concurrent with
a significant increase in the production of HDM-specific IL-5
and IL-13 in the medLN cell cultures from Cd11cCreMap3k8fl/ko
mice (Fig 3, E). As in Map3k82/2 mice (Fig 1, H), we also
observed a significant increase in total levels of circulating IgE in
Cd11cCreMap3k8fl/ko mice (Fig 3, F). These results suggest that
TPL-2 inCD11c1DCnegatively regulated airway inflammation af-
ter HDM challenge.
It was important to determine whether the enhanced allergic
airway responses in Map3k82/2 mice were attributable to DCs
and not to any other CD11c-expressing cells, such as alveolar
macrophages that would delete TPL-2 in Cd11cCreMap3k8fl/ko
mice. To do this, we used a LysMCre driver mouse strain to delete
TPL-2 in LysM-expressing cells, including alveolar macro-
phages. After HDM sensitization and challenge, LysMCre-
Map3k8fl/ko mice mounted a comparable airway inflammatory
response to control mice, with similar airway infiltrates (see Fig
E4, A, in this article’s Online Repository at www.jacionline.
org), comparable pulmonary inflammation (Fig E4, B), lung
mRNA expression for type 2 cytokines (Fig E4, C), and
HDM-specific cytokine secretion by restimulated medLN cells
(Fig E4,D) upon HDM sensitization and airway challenge. These
observations indicated that the exacerbated allergic airway
inflammation observed in TPL-2–deficient mice was not due to
a cell-intrinsic defect of TPL-2 in alveolar macrophages.
To further test whether DC-intrinsic TPL-2 was required to
regulate airway inflammation, we used a well-established adoptive
transfer system usingHDM-pulsed bonemarrow–derived dendritic
cells (BMDCs).1 WT andMap3k82/2 BMDCs (see Fig E5, A and
B, in this article’s Online Repository at www.jacionline.org) were
pulsed overnight with HDM and then transferred via intratracheal
administration into naive WT mice (Fig 4, A). In line with experi-
ments with Map3k82/2 mice and Cd11cCreMap3k8fl/ko mice,
mice receiving a single adoptive transfer of Map3k82/2 BMDCs
followed by 2 intratracheal challenges displayed significantly
increased infiltration of total cells, eosinophils, and lymphocytes
in the BAL fluid compared with mice given HDM-pulsed WT
BMDCs (Fig 4, B). Mice receiving unpulsed WT and Map3k82/2
BMDCs failed to develop any inflammatory response (data not
shown). Augmented pulmonary inflammation was also observed
in mice given HDM-pulsed Map3k82/2 BMDCs compared with
WT BMDCs (Fig 4, C). Adoptive transfer of HDM-pulsed
Map3k82/2BMDCs also resulted in higher levels of ll4 and a trend
toward an increase in Il5mRNA in the lung compared with control
WT BMDCs (Fig 4,D). These observations support the hypothesis
that DC-intrinsic TPL-2 regulated airway and tissue inflammation
after HDM challenge.TPL-2 regulates the expression of Ccl24 by dendritic
cells
Airway allergy induced by an intranasal (i.n.)HDMsensitization
and i.n. challenge regimen (Fig 5, A) is strictly DC-dependent,26
FIG 3. Map3k82/2 mice mount increased allergic responses due to TPL-2 function in CD11c1 DCs. A, Fre-
quency of R26eYFP1 in the CD11c1 DCs from lungs of allergic conditional KO mice. Black bars represent
Cd11cCreMap3k8wt/wt mice, and gray bars represent Cd11cCreMap3k8fl/ko mice. B, Differential counts in the
BAL fluid of allergic conditional KO mice. C, Hematoxylin and eosin–stained histology sections and inflam-
mation scores from allergic lungs of conditional KO mice showing increased cellular infiltration. D, Fre-
quency and total number of cytokine1/CD41/CD44hi cells in the allergic lungs of conditional KO mice as
assessed by intracellular cytokine staining. E, HDM-specific IL-5 and IL-13 protein production as assessed
by ELISA in the medLN cell culture supernatants from allergic conditional KO mice for 4 days. F, Total
IgE in the serum as assessed by ELISA from allergic conditional KOmice. All experiments are representative
of 2 independent experiments with 3 to 5 mice/genotype. *P < .05 as assessed by Mann-Whitney test. KO,
Knockout.
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aluminum hydroxide as an adjuvant. Using this model, we also
observed a significant increase in total BAL cells and eosinophils
in the BAL fluid ofMap3k82/2mice, compared withWT controls
(Fig 5, B). We observed an increase in the frequency of TH2 cells
producing IL-4, IL-5, and IL-13, although this was not statistically
significant, and a significant increase in the total number of IL-4–,
IL-5–, and IL-13–secreting TH2 cells in the lungs of Map3k8
2/2
mice compared with WT controls (Fig 5, C). In addition,
Map3k82/2 medLN cell cultures produced significantly more
IL-5 and a trend toward more IL-13 after HDM restimulation,
compared with WT medLN cell cultures (Fig 5, D). Serum levels
of total IgE were also significantly elevated in Map3k82/2 mice
comparedwithWTcontrols (Fig 5,E). Together, these observations
suggest that TPL-2–mediated control of allergic airway responseswas independent of the route of antigen administration and
independent of any alum adjuvant-associated effects.
To investigate how TPL-2 regulated DC function, we per-
formed fluorescence-activated cell sorting of CD11c1MHC-II1
DCs to high purity (;99%) from the local draining medLNs of
intranasally sensitized WT and Map3k82/2 mice (Fig 5, F) and
performed RNA sequencing. Genomewide transcriptional
analysis of purified DCs identified a number of characteristic
DC-associated genes, which were comparable in both WT and
Map3k82/2 DCs (Fig E5, H).27 To identify transcriptional
differences betweenWTandMap3k82/2DCs, mRNA expression
in Map3k82/2 DCs was compared to that in WT DCs and
statistically significant differences in gene expression were iden-
tified using edgeR analysis (Fig 5, G). Ccl24 (eotaxin-2), which
functions as a potent eosinophil and granulocyte chemoattractant
FIG 4. Adoptive transfer ofMap3k82/2 BMDCs in WT mice mediates increased allergic responses. A, Sche-
matic representation of the adoptive transfer model for HDM-pulsed BMDCs and subsequent HDM chal-
lenge in naive WT mice. B, Differential counts in the BAL fluid of allergic WT mice adoptively transferred
with vehicle control (white bars), WT BMDCs (black bars), or Map3k82/2 BMDCs (gray bars). C, Histology
sections and inflammation scores from allergic lungs of WT mice adoptively transferred with WT,
Map3k82/2 BMDCs, or vehicle control depicting cellular infiltration. D, Lung expression of Il4, Il5, and Il13
mRNA in allergic WT mice adoptively transferred with WT or Map3k82/2 BMDCs or vehicle control. All ex-
periments are representative of 2 to 3 independent experiments with 3 to 8mice/genotype. i.t., Intratracheal.
*P < .05 as assessed by Mann-Whitney test.
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models of airway allergy,29,30 was approximately 5.7-fold
upregulated in Map3k82/2 DCs compared with WT DCs
(Fig 5, G). Interestingly, the expression of Ccr3, the receptor for
Ccl24, on T cells is regulated by IL-4 and IL-231 and has
previously been implicated in the preferential recruitment of
TH2 cells.
32 These data raised the possibility that DC TPL-2
regulated the recruitment of both TH2 cells and eosinophils by
regulating the expression of Ccl24.TPL-2 restricts Ccl24 production to limit severe
allergic airway inflammation
Following the observation that Map3k82/2 DCs had elevated
Ccl24 expression, we evaluated the production of Ccl24 protein
by Map3k82/2 mice after i.n. HDM sensitization and challenge
(Fig 6, A). Ccl24 protein was barely detectable in BAL fluid after
i.n. HDM sensitization (D3) in either WT or Map3k82/2 mice
(Fig 6, B). However, at days 12 and 14 after i.n. challenge,
Ccl24 protein was clearly detected and significantly elevated on
day 12 in the BAL fluid of Map3k82/2 mice compared withWT mice (Fig 6, B). Thus, increased Ccl24 in Map3k82/2
mice correlated with increased allergic responses (Fig 5 and
Fig 6, B).
To determine whether Map3k82/2 DCs were responsible for
elevated Ccl24 in vivo and contributed to the severe allergic re-
sponses, we first evaluated the levels of Ccl24 in the BAL fluid
of WT mice given either HDM-pulsed WT or HDM-pulsed
Map3k82/2 BMDCs (Fig 6, C). Similar to intact WT and
Map3k82/2 mice, we detected very low levels of Ccl24 in the
BAL fluid at day 3 and day 6 after cell transfer (Fig 6, D). How-
ever, at day 11 after HDM challenge, we observed a significant in-
crease in Ccl24 in mice given Map3k82/2 BMDCs compared
with mice given WT BMDCs (Fig 6, D). These results suggested
that the absence of TPL-2 in DCs was responsible for increased
Ccl24 in the BAL of HDM-challenged Map3k82/2 mice, which
correlated with severe airway allergy (Fig 4, B-D, and Fig 6, D).
To test whether elevated Ccl24 in mice receiving Map3k82/2
BMDCs was responsible for severe airway inflammation, we
adoptively transferred HDM-pulsed WT or Map3k82/2 BMDCs
into naive WT mice and neutralized Ccl24 using anti-Ccl24
antibodies (Fig 6, E). As demonstrated above, mice receiving
FIG 5. Expression profiling ofWT andMap3k82/2 DCs in an alum-independentmodel of HDM sensitization.A,
Schematic representation of the alum-independent model of i.n. HDM sensitization and challenge in WT and
Map3k82/2 mice. B, Differential counts in the BAL fluid of PBS- and HDM-challenged WT and Map3k82/2
mice. C, Frequency and total number of cytokine1/CD41/CD44hi cells in the PBS- and HDM-challenged lungs
ofWTandMap3k82/2miceas assessed by intracellular cytokine staining.D,HDM-specific IL-5 and IL-13protein
productionasassessedbyELISA in thecell culture supernatantsofmedLNs fromPBS-andHDM-challengedWT
andMap3k82/2mice for 4 days. E, Total IgE in the serumas assessed by ELISA fromPBS- andHDM-challenged
WTandMap3k82/2mice.F,Schematic representation for isolationofCD11c1/MHC-II1DCsexvivoafter i.n.HDM
sensitization.G, Plot depicting normalized gene expression levels of theMap3k82/2 samples over theWT sam-
ples, reported as fold change. The red data pointsdepict genes upregulated in theMap3k82/2 samples over the
WTsamples, and thebluedata pointsdepict genesdownregulated in theMap3k82/2 samplesover theWTsam-
ples. Gene expression of Ccl24 plotted from the RNA sequencing analysis of CD11c1/MHC-II1 cells ex vivo. All
experiments are representative of 2 independent experiments with 3 to 6mice/genotype. The RNA sequencing
analysis was performed on 3 independent samples/genotype. FACS, Fluorescence-activated cell sorting; i.n.,
intranasal; KO, knockout. *P < .05 as assessed byMann-Whitney test.
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FIG 6. Map3k82/2 BMDCsmediate increased eosinophilia and airway inflammation by regulating the produc-
tion of Ccl24. A, Schematic representation of the time course for evaluating Ccl24 production in WT and
Map3k82/2 mice during the i.n. HDM sensitization and challenge model, as in Fig 5. B, Ccl24 protein in the
BAL fluid of WT and Map3k82/2 mice sensitized and challenged with HDM. C, Schematic representation of
the time course for evaluating Ccl24 production in allergic mice following transfer of HDM-pulsed WT or
Map3k82/2 BMDCs. D, Ccl24 protein in the BAL fluid of allergic mice given HDM-pulsed WT and Map3k82/2
BMDCs.E,Schematic representationof thesetup forneutralizingCcl24 inallergicmice using theadoptive trans-
fer of HDM-pulsedWT orMap3k82/2 BMDCs. F, Total number of all cells, eosinophils, and lymphocytes in the
BAL fluid of allergic WT mice receiving with either HDM-pulsed WT or Map3k82/2 BMDCs and given either
anti-Ccl24 antibody or isotype control. G, Histology sections and inflammation scores from allergic lungs of
WTmice adoptively transferred withWT orMap3k82/2 BMDCs and given either anti-Ccl24 antibody or isotype
control.H,HDM-specific IL-5 and IL-13 protein production as assessed by ELISA in the 4-day cell culture super-
natants ofmedLNs fromHDM-challengedWTmice given eitherWTorMap3k82/2 BMDCs and either anti-Ccl24
antibody or isotype control. All experiments are representative of 2 to 3 independent experiments with 4 to 5
mice/genotype. i.n., Intransal; i.t., intratracheal; i.v., intravenous. *P < .05 as assessed byMann-Whitney test.
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higher airway inflammation with increased eosinophilia and
lymphocyte recruitment (Fig 6, F). Ccl24 blockade had
minimal effect on airway inflammation in mice given WT
BMDCs; however, Ccl24 blockade completely prevented
severe airway inflammation observed in mice given Map3k82/2
BMDCs, compared with the isotype-treated control mice
(Fig 6, F). Specifically, blocking Ccl24 reduced airway
eosinophilia and lymphocyte recruitment in the BAL fluid of
mice given Map3k82/2 BMDCs, compared with isotype-treated
mice (Fig 6, F). The increased pulmonary inflammation observed
in mice given HDM-pulsed Map3k82/2 BMDCs was also
significantly reduced upon neutralization of Ccl24, compared
with isotype-treated mice (Fig 6, G). In addition, allergic mice
transplanted with Map3k82/2 BMDCs had a significant increase
in IL-5 and IL-13 production from restimulated HDM-specific
medLN cultures compared with mice receiving WT BMDCs
(Fig 6, H). This increased type 2 cytokine production in mice
receiving Map3k82/2 BMDCs was significantly reduced upon
neutralization of Ccl24 compared with isotype-treated control
mice (Fig 6, H). Surprisingly, neutralization of Ccl24 also led to
a significant decrease in IL-5 and IL-13 production in mice given
WT BMDCs compared with mice treated with isotype control
(Fig 6, H). There was no significant difference between the type
2 cytokine production in mice given WT or Map3k82/2 BMDCs
along with Ccl24-neutralizing antibody (Fig 6,H). These observa-
tions demonstrated that severe airway allergywith elevated airway
eosinophilia, lymphocyte infiltration, and lung inflammation in
mice receiving Map3k82/2 BMDCs was mediated by Ccl24.
Furthermore, Ccl24 regulated HDM-specific type 2 cytokine pro-
duction from LN cultures, suggesting that Ccl24 also regulated
local lymphocyte recruitment. Collectively, these data identify a
critical role for DC-intrinsic TPL-2 in preventing severe airway
allergic responses to HDM by regulating Ccl24 expression.DISCUSSION
In the present study, we identified that TPL-2 prevented severe
airway allergic responses to HDM, mediated principally by a DC-
intrinsic function of TPL-2. RNA sequencing of draining medLN
DCs identified that TPL-2 critically regulated Ccl24.
Elevated Ccl24 protein was also observed in the BAL fluid of
Map3k82/2 mice after HDM challenge, suggesting that Ccl24
contributed to the severe airway disease in Map3k82/2 mice.
Consistent with this hypothesis, severe airway allergy induced
by adoptive transfer of Map3k82/2 DCs could be blocked by
neutralization of Ccl24. Together, these results indicate that
DC-intrinsic TPL-2 limits severe airway allergic responses by
regulating the production of Ccl24.
The role of TPL-2 in regulating type-1 and TH17 inflammatory
responses has been extensively investigated.9,10,16,17 In contrast,
only a single study has reported a role for TPL-2 in type 2 re-
sponses.19 In agreement withWatford et al,19 our study confirmed
that TPL-2 inhibits type 2 responses. However, the present study,
using a more physiologically relevant allergen (HDM) and in
several models of airway allergy, clearly demonstrated that
TPL-2 expression in T cells was not important in airway allergic
responses. This contrasts with the conclusions of this earlier study
in which in vitro experiments suggested that a T-cell–intrinsic role
for TPL-2 was required to limit type 2 responses.19 Our results
clearly demonstrated that TPL-2 was not required for TH2differentiation in vitro and by restricting the deficiency of TPL-
2 to T cells, using mixed BM chimeras or T-cell conditional
knockout mice, it was evident that T-cell–intrinsic TPL-2 had
no role in regulating type 2 responses in vivo.
A critical role of DCs in initiating and activating allergic type 2
responses has previously been demonstrated.26,33 However, the
molecular mechanisms by which DCs initiate type 2 response
are incompletely understood. We did not observe any appreciable
differences in the frequency or total number of different DC sub-
sets (CD11b1 cDCs, CD1031 DCs, CD641/FcεRIa1 inflamma-
tory DCs, PDCA11 plasmacytoid DCs) between WT and
Map3k82/2mice at baseline or after HDM sensitization and chal-
lenge either in the lung or in medLNs, suggesting that TPL-2 did
not regulate the development or recruitment of different DC sub-
sets (Fig E5, E andF). However, we demonstrated that TPL-2 was
an important regulator of DC-derivedCcl24, limiting the develop-
ment of severe airway allergic responses to HDM. On the basis of
experiments with Cd11cCreMap3k8fl/ko mice, LysMCreMap3k8fl/fl
mice, and adoptive transfer experiments with BMDCs and using
an intranasal sensitization and challenge system, we established
that DC-intrinsic TPL-2 provided an important regulatory role
to prevent the development of severe airway allergy. Strikingly,
a single adoptive transfer of HDM-pulsed Map3k82/2 DCs reca-
pitulated many of the features of severe airway allergy, including
increased airway and tissue inflammation, similar to HDM-
challenged Map3k82/2 mice.
Although the array of model systems used in this study
converged upon a dominant DC-intrinsic role for TPL-2 in
regulating airway and tissue inflammation, several differences
also emerged between the model systems. These may be due to
additional roles for TPL-2 in other cellular compartments,
different routes of sensitization, frequency of airway challenges,
and time of analysis. Furthermore, within the DC-specific
systems, the role of different DC subsets and different CD11c-
expressing cells may also contribute to different aspects of the
allergic response. Additional comparative studies using both
human and murine DC subsets from allergic and nonallergic
individuals are needed to delineate the role of TPL-2 in regulating
DC function.
To identify how DC-intrinsic TPL-2 regulated airway allergic
responses, we compared the transcriptome of ex vivo CD11c1/
MHC-II1 DCs from WT and Map3k82/2 mice using a well-
established model of DC-dependent HDM- mediated airway al-
lergy.22 Increased allergic responses in Map3k82/2 mice using
this i.n. model indicated that TPL-2 inhibited airway allergic re-
sponses independent of the intraperitoneal priming or the poten-
tial impact of the aluminum hydroxide adjuvant. Previous
studies have described a range of DC-expressed molecules,
including CD40, CD80/86, and OX40, required to activate TH2
immunity.34-37 We did not observe differential expression of
any of these molecules between Map3k82/2 and WT DCs (Fig
E5, B and G). Our earlier work also established that TPL-2
regulates the expression of Il12 p35, Il12 p40, Il10, and Ifnb in
TLR-activated DC.10 However, we did not observe differential
regulation of any of these cytokines in in vitro HDM-pulsed
Map3k82/2 DCs (Fig E5, C). TPL-2 has been previously shown
to regulate IFN-g and type 1 responses.15,16 However, following
HDM-induced airway responses, we did not observe any signifi-
cant difference in lung Ifng, between the allergic conditional
knockout mice in the CD11cCre model (Fig E5, D), indicating
that type 1 responses were intact in mice with TPL-2–deficient
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Map3k82/2 mice had significantly reduced expression of Ifng,
compared with allergic WT mice (Fig 1, E), suggesting
CD11c1 cell independent control of Ifng expression in
Map3k82/2 mice following HDM sensitization and challenge.
These differences suggest that DC-intrinsic TPL-2 regulates
HDM-driven type 2 responses in a context-dependent manner,
compared with type 1/TLR-mediated responses.
Ccl24 (eotaxin-2) is a chemoattractant for CCR3-expressing
cells, predominantly eosinophils and TH2 lymphocytes,
32,38 and
may contribute to airway remodeling.39 Hallmark features of
type 2 human allergic asthma are circulating, airway, and tissue
eosinophils accompanied by elevated TH2 lymphocytes, suggest-
ing a mechanistic link between elevated DC expression of Ccl24,
observed in this study, and elevated airway eosinophilia and type
2 immune responses. Although elevated Ccl24 has been observed
in IL-4–treated, type 2–promoting BMDCs and ex vivoDCs from
allergic mice,33,40 the functional relevance of DC-derived Ccl24
was not investigated in these studies. Murine studies presented
here identified that Map3k82/2 DCs were sufficient to invoke
elevated levels of Ccl24 in the airways of mice following adoptive
transfer, concomitant with increased eosinophilia and lympho-
cyte recruitment, highlighting the importance of Ccl24 in driving
a severe allergic response.
The expression of CCR3 on TH2 cells
32 provides a potential
mechanistic explanation for how DC-derived Ccl24 could pro-
mote TH2-driven responses. Consistent with this, neutralizing
Ccl24 dramatically reduced airway eosinophilia, lymphocyte
infiltration, and lung inflammation in allergic mice given
Map3k82/2 BMDCs, highlighting a key role of Ccl24 in medi-
ating severe airway allergy in Map3k82/2 mice.
It will be important to determine whether TPL-2 also regulates
CCL24 in humanDCs andwhether the TPL-2 pathway is compro-
mised in thosewith severe asthma. In support of this, sputum from
patients with severe, treatment-refractory asthma had elevated
levels of Ccl24, compared with the sputum of those with nonse-
vere asthma.41 Similarly, elevated expression of tissue Ccl24
has been observed in those with severe asthma, correlating with
sputum eosinophilia, lower FEV1, and more asthma exacerba-
tions.42 In addition, polymorphisms in the CCL24 gene have
been associated with the development of asthma.43 These data
support the notion that elevated Ccl24 may contribute to severe
airway allergy and maybe a useful biomarker to identify patients
with severe asthma44 and supports the hypothesis that dysregu-
lated TPL-2 in DCs may contribute to elevated Ccl24 in those
with severe asthma; however, this needs to be tested.
Although we demonstrated that Ccl24 was an important
mediator of severe allergic responses in mice, it was interesting
to note that blockade of Ccl24 had little effect on the allergic
airway responses in mice given WT BMDCs, most likely due to
the lower levels of Ccl24 observed in the BAL fluid of mice given
HDM-pulsed WT DCs or i.n. HDM (Fig 6). These data suggest
that dysregulated Ccl24 may be responsible for the transition
from moderate to severe asthma in mice and that other mediators,
such as Ccl11 (eotaxin-1) and IL-5, may contribute to airway
inflammation in moderate asthma that developed in WT mice.
In support of this observation, Ccl24-deficient mice are capable
of mounting low levels of airway eosinophilia after ovalbumin
challenge.30 It is also possible that IL-5, Ccl11, and Ccl24 syner-
gistically contribute to severe airway inflammation. Indeed, the
coexpression of Ccl11 and Ccl24,45 or IL-5 and Ccl24,46correlates with persistent airway eosinophilia in mice with severe
airway allergy.
In conclusion, we have demonstrated that TPL-2 negatively
regulates type 2 responses to HDM, preventing the development
of severe airway allergic responses. Cell-intrinsic functions in
T cells and B cells in airway allergic responses were ruled out,
whereas TPL-2 expression in DCs was shown to be essential to
regulate the expression of Ccl24 in the lungs after HDM
challenge. Antibody-blocking experiments confirmed the impor-
tance of elevated Ccl24 in driving severe airway inflammation in
Map3k82/2mice. Further study is required to determine whether
TPL-2 regulates chemokine secretion, including Ccl24, in human
cells and whether alterations in TPL-2 expression/signaling
contribute to severe asthma. TPL-2 is widely considered as a
promising anti-inflammatory drug target.47 However, the results
in the present study suggest that TPL-2 inhibitors could have un-
wanted impacts on allergic comorbidities.
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Animals
All micewere bred andmaintained under specific pathogen-free conditions at
the Francis Crick Institute. Strains used includedWTC57BL/6,Map3k82/2E1 on
a C57BL/6 background, Il4GFPFoxp3RFP10BIT (B6.Il4GFP crossed with
B6.Foxp3RFP.10BIT), Map3k82/2Il4GFPFoxp3RFP10BIT (Map3k82/2 crossed
with Il4GFPFoxp3RFP10BIT), Cd4CreMap3k8flflR26eYFP (B6.Cd4Cre crossed with
Map3k8flfl and B6.R26eYFP), Tcra2/2 (B6.129S2-Tcratm1Mom/J),
MuMT(B10.129S2(B6)-Ighmtm1Cng/J), C57BL/6 Rag12/2, C57BL/6 Rag22/2,
Cd11cCreMap3k8flflR26eYFP (B6.Cd11cCre crossed with Map3k8flfl and
B6.R26eYFP), and LysMCreMap3k8flflR26eYFP (B6.LysMCre crossed with
Map3k8flfl and B6.R26eYFP). All animal experiments were carried out following
UK Home Office regulations (project license 80/2506) and were approved by
the Francis Crick Institute Ethical Review Panel.
HDM-induced airway inflammation
As indicated, mice were sensitized twice via the intraperitoneal route with
100 mg (dry weight) of HDM (Dermatophagoides pternoyssinus extracts,
Greer, Lenoir, NC), ovalbumin (10 mg, Sigma, St Louis, Mo), or Der p1
(10 mg; Greer) with Imject Alum (Thermoscientific, Waltham, Mass) diluted
in PBS (1:3) solution. After sensitization, mice were challenged twice
with 100 mg of HDM, Der p1, or ovalbumin, as indicated, and diluted intratra-
cheally in PBS on days 21 and 24. All the parameters for airway allergy were
measured 1 day after the last challenge.
Intranasal sensitization and challenge model
Mice were sensitized intranasally with 100 mg of HDM diluted in PBS and
subsequently challenged intranasallywith 10mg ofHDMover a period of 5 days
fromday7 today 11.All the parameters for airwayallergyweremeasured 3 days
after the last challenge.
BMDC culture and adoptive transfer
BM cells were cultured in the presence of 20 ng/mL GM-CSF (Peprotech,
London, United Kingdom) for 10 days. For HDM pulsing, BMDCs were washed
and cultured overnight with HDM (10 mg) and 5 ng/mL GM-CSF. The adoptive
transfer model has been previously described.E2 Briefly, mature DCs were
cultured overnight with 10 mg of HDM, washed with PBS, and transferred intra-
tracheally into naive WT mice. After the initial transfer, mice were challenged
with 100mg of HDM diluted intratracheally in PBS on days 7 and 10. All the pa-
rameters for airway allergyweremeasured 1 day after the last challenge.Blocking
antibodies diluted in PBS (Ccl24 antibodies [CCL24/eotaxin-2 MAb (Clone
106521, R&D Systems–Biotechne, Minneapolis, Minn) and CCL24/eotaxin-2
Affinity Purified Polyclonal Ab, R&D Systems–Biotechne]) were mixed and
used at 0.03mg/dose (monoclonal) and 0.006 mg/dose (polyclonal). Isotype con-
trols rat IgG2A (Clone 54447, R&D systems–Biotechne) and normal goat IgG
(R&D systems–Biotechne) were mixed and used in similar ratios.
Chimeric mice
C57BL/6 Rag12/2 or C57BL/6 Rag22/2 mice were irradiated with 900
RADs. For the T-cell–restricted chimeras, 23 106 to 53 106 mixed BM cells
of Tcra2/2 and Il4GFPFoxp3RFP10BIT or Map3k82/2 Il4GFPFoxp3RFP10BIT
(ratio 80:20) were injected intravenously. For the B-cell–restricted chimeras,
2 3 106 to 5 3 106 mixed BM cells of MuMT and Il4GFPFoxp3RFP10BIT or
Map3k82/2 Il4GFPFoxp3RFP10BIT (ratio 80:20) were injected intravenously.
After 8 weeks, mixed BM chimeric mice were sensitized and challenged
with HDM, as described above.
Airway resistance measurements
Baseline and methacholine-induced airway hyperreactivity measurements of
conscious, restrained mice were obtained using a Buxco FinePointe System for
noninvasive airway measurement (Buxco Research Systems, Wilmington, NC)
according to the manufacturer’s instructions. Mice were exposed to aerosolised
methacholine (Sigma), administered from 3 to 50 mg/mL for a 5-minute period
(30 seconds dosing, 2 minutes recording, and 2.5 minutes recovery), with airway
resistance measurements made during the 2 minutes of recording.BAL fluid preparation and differential cell counts
One day after the last HDM challenge, mice were culled and BAL fluid
collected using 1.5mLof PBS for eachmouse. BALfluidwas centrifuged at 300g
for 10minutes at 48Cand cells resuspended in equal volumes of complete Iscove’s
modified Dulbecco’s medium (IMDM) (Sigma) (with 10% FCS, 1% 100 U/mL
penicillin and 100 mg/mL streptomycin [Gibco, Waltham, Mass], 8 mM L-gluta-
mine [Gibco], and 0.05 mM 2-mercaptoethanol [Gibco]). The BAL fluid was
stored at 2808C before analysis. The total number of BAL cells was counted
and differential cell counts performed on cytospin preparations stained with Gi-
emsa stain, modified (Sigma).
Histology and inflammation scoring
Excised lungs were fixed in 10% neutral buffered formalin overnight and
washed in 75% ethanol. The tissues were embedded in paraffin, and lung
sections were stained with hematoxylin and eosin stain. Stained slides were
scanned with a VS120-SL slide scanner (Olympus, Tokyo, Japan) and images
were analyzed with the OlyVIA image viewer (Olympus). Inflammation
scoring was performed as previously described.E3
Isolation of lung and medLN cells
Mice were culled, bled, and lungs and medLNs collected. Lungs were
homogenized and lymphocytes enriched by density gradient centrifugation
using 40% Percoll (GE Healthcare, Little Chalfont, United Kingdom).
Homogenized medLN cells were cultured at a density of 200,000 cells/well
in 200 mL in 96-well round-bottom plates (Sigma) for 4 days, with 10 mg/mL
HDM.
Isolation of DCs
For the isolation of ex vivoDCs, medLNs from HDM-sensitized mice were
homogenized and separated on a density gradient. To do this, cells were resus-
pended in a 15% w/v solution of OptiPrep (Sigma) and overlayed with the
diluent solution (0.88% w/v sodium chloride, 1 mM ethylene-diamine-tetra-
acetic acid, 0.5% w/v BSA, 10 mM Hepes-NaOH, pH 7.4) and IMDM. Sam-
ples were centrifuged at 600g for 15 minutes at room temperature and the en-
riched DC layer was collected from the top of the gradient for downstream
analysis.
Cell sorting and flow cytometry
Cell sorting was performed using a FACS Aria II (BD Biosciences, San
Jose, Calif) cell sorter. For sorting, cell suspensions were stained for
20 minutes with antibodies in PBS with 2% FCS and then diluted in
phenol-red free IMDM (Gibco) (with 1% FCS, 2 mM EDTA [Invitrogen],
100U/mL penicillin and 100mg/mL streptomycin [Gibco], 8mML-glutamine
[Gibco], and 0.05 mM 2-mercaptoethanol [Gibco]). Propidium iodide or
LIVE/DEAD fixable blue dead cell stain (Life Technologies) was used to
determine cell viability. Cells were stained for surface antigens by incubation
with antibodies in PBS with 2% FCS (20 minutes at 48C). Intracellular cyto-
kine staining was performed after 6 hours of restimulation with 50 ng/mL
phorbol 12-myristate 13-acetate (Promega, Madison, Wis) and 1 mg/mL ion-
omycin (Sigma) and BD Golgi Stop and BD Golgi Plug (diluted 1:1000, BD
Biosciences). After staining for surface antigens, cells were fixed and permea-
bilized (Fixation/Permeabilization diluent; eBioscience, San Diego, Calif),
before incubation with cytokine antibodies in permeabilization buffer (eBio-
science) for 20 minutes at 48C. Cells were analyzed using a BD LSRII flow
cytometer (BD Biosciences) and data processed using FlowJo software
(Version X 10.0.7r2, Treestar Inc, Ashland, Ore). Antibodies used were pur-
chased from eBioscience, Biolegend (San Diego, Calif), or BD Pharmingen
(San Diego, Calif). They include CD3 (17A2), CD4 (RM4-5, GK1.5),
CD11b (M1/70), CD11c (N418), CD19 (6D5, eBio1D3), CD25 (PC61),
CD44 (IM7), CD45 (30-F11), CD49b (DX5), CD64 (X54-5/7.1), CD69
(H1.2F3), CD80 (16-10A1), CD86 (GL1), CD103 (2E7), CD197 (4B12),
CD278 (C39.4A), F4/80 (BM8), FceRI (MAR-1), GATA-3 (L50-823), Gr-1
(RB6-8C5) (IFN-g) (XMG1.2), I-A/I-E (M5/114.15.2), IL-4 (11B11), IL-5
(TRFK5), IL-13 (eBio13A), KLRG1 (2F1), Ly6G (1A8), NK1.1 (PK136),
PDCA1 (927), SiglecF (E50-2440), TCR b chain (H57-597), TCRgd
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cell staining was defined as CD41/CD81/CD31/CD191/TCRb1/
TCRgd1/NK1.11/CD49b1/CD11c1/CD11b1/Gr-11/Ter1191. Staining
was performed in the presence of FcR Blocking Reagent (Miltenyi Biotec,
Bergisch Gladbach, Germany).
TH2 polarization
Naive CD41T cells were sorted from spleens ofWTorMap3k82/2mice as
CD41TCRb1CD442CD252PI2. They were cultured for 6 days in vitro with
10 ng/mL IL-4 (R&DSystems–Biotechne, Minneapolis, Minn), 5 ng/mL IL-2
(R&D), 10 mg/mL anti–IFN-g (XMG1.2, BioXcell, West Lebanon, NH), and
CD3 (0.1-4.0 mg) (145-2C11, BioXcell) and CD28 (10 mg/mL) (37.51, Bio-
Xcell) in IMDM with 10% FCS (and other components as listed above).
RT-PCR, ELISA, and Western blotting
Tissue samples were frozen in RNAlater (Sigma) and homogenized in
QIAzol (Qiagen, Hilden, Germany). Cell pellets were lysed in Buffer RLT
(Qiagen). Total RNA was isolated as per manufacturer’s protocol. Total
RNA (100 ng-1 mg) was reverse transcribed using the QuantiTect Reverse
Transcription Kit (Qiagen). cDNA produced was used for real-time quantita-
tive PCR with Power SyBrGreen (Applied Biosystems, Foster City, Calif).
The expression levels of different genes (Ifng [forward: ACAGCCAGAT-
TATCTCTTTCTACCTCAG; reverse: CCTTTTTCGCCTTGCTGTTG], Il4
[forward: ACGAGGTCACAGGAGAAGGGA; reverse: AGCCCTACAGAC
GAGCTCACTC], Il5 [forward: TGACAAGCAATGAGACGATGAGGG;
reverse: ACCCCCACGGACAGTTTGATTC], Il13 [forward: CCTCT
GACCCTTAAGGAGCTTAT; reverse: CGTTGCACAGGGGAGTCTT],
Il1b [forward: GGAGAACCAAGCAACGACAAAATA; reverse: TGGG
GAACTCTGCAGACTCAAAC], Il6 [forward: TCCAGTTGCCTTCTTGG
GAC; reverse: GTGTAATTAAGCCTCCGACTTG], Il12p35 [forward: GAG
GACTTGAAGATGTACA; reverse: TTCTACTTGGAGGAGGGC], Il12
p40 [forward: GACCCTGCCGATTGAACTGGC; reverse: CAACGTTG
CATCCTAGGATCG], Il10 [forward: ATGCTGCCTGCTCTTACTGACTG;
reverse: CCCAAGTAACCCTTAAAGTCCTGC], and Ifnb [forward:
GCACTGGGTGGAAGTAGACT; reverse: AGTGGAGAGCAGTTGAG
GACA]) were normalized to hypoxanthine-guanine phosphoribosyl trans-
ferase expression and expressed as fold change relative to naive or PBS-
treated WT samples. Ccl24, IL-5, and IL-13 were measured using DuoSet
ELISA kits, according to the manufacturer’s instructions (R&DSystems–Bio-
techne). Total IgE ELISA was performed by coating with purified rat anti-
mouse IgE (R35-72, BD Pharmingen) at 2 mg/mL overnight, followed by
overnight incubation with serum and standard (purified mouse IgE,
k isotype standard, BD Pharmingen), and detection with Biotin rat antimouseIgE at 1 mg/mL (R35-118, BD Pharmingen), Streptavidin HRP (BD Pharmin-
gen), and TMB ELISA substrate (eBioscience). For immunoblotting, cell ly-
sates were normalized to equal total protein content and resolved on 10%
Criterion TGX Gels (Biorad, Hercules, Calif). Separated proteins were trans-
ferred onto Trans-Blot Turbo PVDF transfer (Biorad) membranes. Specific
bound antibodies were visualized by chemiluminescence (Immobilon; Merck
Millipore, Darmstadt, Germany).
RNA Sequencing
Raw Illumina reads were analyzed as follows. First, data quality was
analyzed using FastQC (www.bioinformatics.babraham.ac.uk/projects/
fastqc). Low-quality bases were trimmed using Trimmomatic.E4 Read pairs
that passed the trimming quality filters were then aligned to mm10 (Ensembl
version 75) using Tophat2.E5 Counts were determined using htseq_count.E6
Normalization and statistical analysis were performed using edger.E7 Statisti-
cally significant genes with a false discovery rate (FDR) of less than 0.05 are
reported.
Statistical analysis
Data sets were compared by using the Mann-Whitney test using GraphPad
Prism (V.5.0). Differences were considered significant at a P value of .05 or
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FIG E1. Allergic airway responses in WT and Map3k82/2 mice. A, Total
number of lung eosinophils (SiglecF1/CD11c2) in PBS-treated and allergic
WT and Map3k82/2 mice as assessed by ICS. B, Frequency of IL-51 and
IL-131 Lin-/Thy1.21/KLRG11 group 2 innate lymphoid cells in the allergic
lungs of WT and Map3k82/2 mice as assessed by ICS. C and D, Total and
eosinophilic counts in the BAL fluid of WT and Map3k82/2 mice sensitized
with alum and Der p1 via the i.p. route and challenged with Der p1 intratra-
cheally. E and F, Total and eosinophilic counts in the BAL fluid of WT and
Map3k82/2 mice sensitized with alum and OVA via the i.p. route and chal-
lenged with OVA intratracheally. All experiments are representative of 2
to 3 independent experiments with 4 to 5 mice/genotype. ICS, Intracellular
cytokine staining; i.p., intraperitoneal; OVA, ovalbumin. *P < .05 as as-
sessed by the 2-tailed Mann-Whitney test.
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FIG E2. Role of TPL-2 function in CD41 cells upon HDM sensitization and challenge. A, Frequency of
R26eYFP1 in the CD41 T-cell compartment from lungs of allergic conditional KO mice. Black bars represent
Cd4CreMap3k8fl/wt mice, and gray bars represent Cd4CreMap3k8fl/ko mice. B, Protein expression of TPL-2
(Santa Cruz Biotechnology, Dallas, Tex) and tubulin in splenic CD41/R26eYFP1 T cells from conditional KO
mice assessed by western blotting. For the WT cells, CD41 T cells were isolated as control. C, Differential
counts in the BAL fluid of allergic Cd4Cre conditional KO mice. D, Hematoxylin and eosin–stained histology
sections and inflammation scores from allergic lungs of Cd4Cre conditional KO mice. E, Lung expression of
Il4, Il5, and Il13mRNA in allergic Cd4Cre conditional KO mice. F, HDM-specific IL-5 and IL-13 protein produc-
tion as assessed by ELISA in the culture supernatants of medLN cells from allergic Cd4Cre conditional KO
mice for 4 days. G, Frequency of IL-41/CD41/CD44hi cells in 6d in vitro polarized TH2 cultures of naive
T cells isolated fromWT andMap3k82/2mice as assessed by intracellular cytokine staining. All experiments
are representative of 3 independent experiments with 4 to 6 mice/genotype. KO, Knockout.
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FIG E3. Severe allergic responses inMap3k82/2mice independent of TPL-2 function in B cells. A, CD191 B-
cell reconstitution in the lung and medLNs of PBS- and HDM-challenged chimeric mice. White bars repre-
sent PBS-challenged chimeric mice with WT B cells, black bars represent HDM-challenged chimeric mice
with WT B cells, light gray bars represent PBS-challenged chimeric mice with Map3k82/2 B cells, and
dark gray bars represent HDM-challenged chimeric mice with Map3k82/2 B cells. B, Differential counts in
the BAL fluid of PBS- and HDM-challenged chimeric mice. C, H&E-stained lung histology sections and
inflammation scores from PBS-challenged and allergic chimeric mice. D, Frequency and total number of
IL-4GFP1/CD41/CD44hi cells in the lungs of PBS- and HDM-challenged chimeric mice. E, Lung expression
of Il4, Il5, and Il13mRNA in PBS- and HDM-challenged chimeric mice. F, HDM-specific IL-5 and IL-13 protein
production as assessed by ELISA in the medLN cell culture supernatants from PBS- and HDM-challenged
chimeric mice for 4 days. All experiments are representative of 2 independent experiments with 4 to 5
mice/genotype.
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FIG E4. Role of TPL-2 function in LysM1 cells upon HDM sensitization and challenge. A, Differential counts
in the BAL fluid of allergic LysMCre conditional KO mice. B, Hematoxylin and eosin–stained histology sec-
tions and inflammation scores from allergic lungs of LysMCre conditional KO mice. C, Lung expression of
Il4, Il5, and Il13 mRNA in allergic LysMCre conditional KO mice. D, HDM-specific IL-5 and IL-13 protein pro-
duction as assessed by ELISA in the culture supernatants of medLN cells from allergic LysMCre conditional
KO mice for 4 days. All experiments are representative of 3 independent experiments with 4 to 6 mice/ge-
notype. KO, Knockout.
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FIG E5. Characterization of WT andMap3k82/2 DCs. A, Frequency of CD11c expression in HDM-stimulated
WT and Map3k82/2 BMDCs. B, MFI of antigen-presenting MHC-II molecule and costimulatory molecules
CD80 and CD86 in HDM-stimulated WT and Map3k82/2 BMDCs. C, Relative expression of previously iden-
tified targets (Il1b, Il6, Il12 p35, Il12 p40, Il10, and Ifnb) of TPL-2 in HDM-stimulated WT and Map3k82/2
BMDCs. D, Lung expression of Ifng mRNA in allergic Cd11cCre conditional KO mice. E and F, Frequency
and total number of different subsets of CD11c1 DCs in the lung and medLNs of PBS- and
HDM-challenged WT and Map3k82/2 mice as assessed by intracellular cytokine staining. G, Normalized
expression of DC-associated genes in ex vivo WT and Map3k82/2 DCs. H, Normalized expression of core
cDC signature genes different from macrophages in ex vivo WT and Map3k82/2 DCs. All experiments are
representative of 2 to 3 independent experiments with 3 to 5mice/samples per genotype. cDC, Conventional
DCs; KO, knockout; MFI, mean fluorescence intensity; pDC, plasmacytoid DCs.
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